Lilly IL-17A inhibitor Taltz (ixekizumab) Phase 3 clinical trial reaches primary endpoint and all important secondary endpoints

axial spinal arthritis (axSpA) is a chronic inflammatory disease that mainly affects the shin joints and axial bones, with approximately 4.5 million adult patients worldwidetoday, Lilly(http://announced today that taltz (ixekizumab), an IL-17A inhibitor developed by the company, has reached the primary and all important secondary endpoints in theof the Phase 3 clinicaltrial
(http://for the treatment of non-radioactive axial axial spinal arthritis (nr-axSpA)this result supports Taltz's use in treating nr-axSpA patients, which, if approved by theFDA(http://, could become the first IL-17A antagonist to treat nr-axSpATaltz is an anti-IL-17A monoclonal antibody that prevents it from binding to IL-17 receptors by binding specifically to IL-17AIL-17A is a naturally occurring cytokine associated with inflammation and immune responseTaltz reduces the symptoms of inflammatory disease by inhibiting the signaling pathway sway mediated by IL-17 receptors, which inhibits the release of inflammatory cytokines and chemical factorsIt has been approved for the treatment of psoriasisIn this randomized double-blind, placebo-controlled multicenter clinical trial called COAST-X, patients who have not received treatment with the bio-resosymptomatic anti-rheumatic drug (http:// (bDMARD) were treated with Taltz or placebo trial data showed that Taltz reached the main endpoint of the trial at 16 and 52 weeks of treatment, and that patients were statistically significantly reduced by testing (http:// by assasal assessment tests COAST-X is part of Lilly's COAST clinical program to treat axSpA patients, and the COAST-V and COAST-W clinical trials treating other types of axSpA patients have also yielded positive results